JP2025505434A - タンパク質構造変化に基づくバイオ医薬プロドラッグプラットホーム - Google Patents

タンパク質構造変化に基づくバイオ医薬プロドラッグプラットホーム Download PDF

Info

Publication number
JP2025505434A
JP2025505434A JP2024545121A JP2024545121A JP2025505434A JP 2025505434 A JP2025505434 A JP 2025505434A JP 2024545121 A JP2024545121 A JP 2024545121A JP 2024545121 A JP2024545121 A JP 2024545121A JP 2025505434 A JP2025505434 A JP 2025505434A
Authority
JP
Japan
Prior art keywords
proteinaceous
seq
protein
loop
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505434A5 (https=
Inventor
ショーンディーン・ルケ・ハーウッド
ヤン・ヨハネス・エングヒルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus Universitet
Original Assignee
Aarhus Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aarhus Universitet filed Critical Aarhus Universitet
Publication of JP2025505434A publication Critical patent/JP2025505434A/ja
Publication of JP2025505434A5 publication Critical patent/JP2025505434A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024545121A 2022-01-31 2023-01-31 タンパク質構造変化に基づくバイオ医薬プロドラッグプラットホーム Pending JP2025505434A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22154258 2022-01-31
EP22154258.2 2022-01-31
PCT/EP2023/052280 WO2023144412A1 (en) 2022-01-31 2023-01-31 A biopharmaceutical prodrug platform based on protein conformational change

Publications (2)

Publication Number Publication Date
JP2025505434A true JP2025505434A (ja) 2025-02-26
JP2025505434A5 JP2025505434A5 (https=) 2026-01-29

Family

ID=80118874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545121A Pending JP2025505434A (ja) 2022-01-31 2023-01-31 タンパク質構造変化に基づくバイオ医薬プロドラッグプラットホーム

Country Status (7)

Country Link
US (1) US20240374745A1 (https=)
EP (1) EP4473007A1 (https=)
JP (1) JP2025505434A (https=)
CN (1) CN118613501A (https=)
AU (1) AU2023211165A1 (https=)
CA (1) CA3243392A1 (https=)
WO (1) WO2023144412A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024261212A1 (en) * 2023-06-22 2024-12-26 Aarhus Universitet Multi-specific proteinaceous prodrug constructs
WO2025128434A1 (en) * 2023-12-14 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of ven/aza resistant acute myeloid leukemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2324864A1 (en) * 1998-04-01 1999-10-07 Duke University Immune response modulator alpha-2 macroglobulin complex
SG175602A1 (en) * 2006-07-05 2011-11-28 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
JP6861152B2 (ja) * 2014-11-20 2021-04-21 サイトニックス コーポレイション 治療用変異体アルファ２−マクログロブリン組成物
EP3762406A2 (en) * 2018-03-09 2021-01-13 Askgene Pharma, Inc. Cytokine prodrugs
AU2019271148B9 (en) * 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222282A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain

Also Published As

Publication number Publication date
CN118613501A (zh) 2024-09-06
CA3243392A1 (en) 2023-08-03
US20240374745A1 (en) 2024-11-14
WO2023144412A1 (en) 2023-08-03
EP4473007A1 (en) 2024-12-11
AU2023211165A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
JP7293456B2 (ja) 誘導性結合タンパク質及びその使用方法
JP7490853B2 (ja) 拘束され、条件的に活性化された結合タンパク質
JP6995151B2 (ja) ｓｙｎＴａｃポリペプチド及びその使用
JP7460609B2 (ja) 活性化可能なインターロイキン－２ポリペプチド及びその使用方法
US20240327527A1 (en) Activatable antibodies and methods of use thereof
CN104704001B (zh) Asgpr抗体及其用途
CN114390938B (zh) 受约束的条件性活化的结合蛋白
US20240374745A1 (en) Biopharmaceutical prodrug platform based on protein conformational change
JP2023540533A (ja) ヒト血清アルブミンドメインを有する、制約され、条件付きで活性化された結合タンパク質構築物
JP2023515573A (ja) 普遍的な遮蔽性部分を有する活性化可能な抗原結合性タンパク質
JP2024547125A (ja) 免疫グロブリン分解酵素ＩｄｅＥの変異体の用途
KR20240111753A (ko) 개선된 항원 결합 수용체
IL294388A (en) il2 orthologs and methods of use
AU2024312715A1 (en) Multi-specific proteinaceous prodrug constructs
WO2025140627A1 (zh) 融合抗体及其应用
RU2800034C2 (ru) Индуцибельные связывающие белки и способы использования
JP2026501783A (ja) Ｓｍａｇｐ融合分子およびその使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260121